Publications by authors named "Y Takasago"
Purpose: To compare anti-vascular endothelial growth factor (anti-VEGF) monotherapy with anti-VEGF therapy combined with sub-Tenon's capsule injections of triamcinolone acetonide (STTA) in patients with macular edema (ME) associated with branch retinal vein occlusion (BRVO).
Study Design: Retrospective observational study METHODS: This study included 186 eyes: 138 eyes received intravitreal injection of ranibizumab (IVR), and the remaining 48 eyes received IVR combined with STTA therapy. If additional IVR were necessary, STTA were performed simultaneously.
Article Synopsis
- The pachychoroid concept has reshaped the understanding of age-related macular degeneration (AMD), revealing a connection with central serous chorioretinopathy (CSC).
- A large genome-wide association study identified two new genetic loci linked to CSC susceptibility in a diverse sample of 1546 CSC patients and 13,029 controls.
- The findings highlight that certain risk alleles, specifically at rs13278062, are associated with both CSC and AMD, enhancing the understanding of the genetic factors involved in these diseases.
Purpose: To evaluate the effect of ranibizumab on retinal oximetry in eyes with diabetic macular oedema (DME).
Methods: In this prospective interventional study, 30 eyes (30 patients) with DME were treated with three-monthly intravitreal ranibizumab injections, followed by pro re nata administration for 12 months. Retinal oximetry was performed using an Oxymap T1.
Purpose: To measure retinal oxygen saturation (SO ) in eyes with branch retinal vein occlusion (BRVO).
Methods: Retinal oximetry was performed using the Oxymap T1 retinal oximeter in 50 eyes (50 patients) with resolved BRVO. SO was calculated in each major retinal artery and vein in four quadrants.
Purpose: To investigate longitudinal changes in metamorphopsia associated with branch retinal vein occlusion.
Methods: In this prospective observational case series, we included 32 eyes (32 patients) with branch retinal vein occlusion and acute macular edema. Eyes were treated as needed with intravitreal ranibizumab injections for 12 months.